- DIAZA-BENZOFLUORANTHRENE COMPOUNDS
-
Disclosed are a series of diaza-benzofluoranthrene compounds. The present invention particularly relates to a compound represented by formula (I), pharmaceutically acceptable salts or tautomers thereof.
- -
-
Paragraph 0450; 04561; 0452
(2018/02/27)
-
- BENZOISOQUINOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
-
The present invention is directed to substituted benzoisoquinolinone compounds, their salts, pharmaceutical compositions comprising them and their use in therapy. In particular, the invention is directed substituted benzoisoquinolinone compounds which are muscarinic M1 receptor positive allosteric modulators. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M1 receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M1 receptors are involved.
- -
-
Page/Page column 28; 29
(2018/02/28)
-
- MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
-
The present invention relates to compounds of formula (I), or their isotopic forms, stereoisomers, tautomers or pharmaceutically acceptable salt (s) thereof as muscarinic M1 receptor positive allosteric modulators (M1 PAMs). The present invention describes the preparation, pharmaceutical composition and the use of compound formula (I).
- -
-
Page/Page column 52
(2018/03/25)
-
- QUINAZOLINE COMPOUNDS USEFUL AS M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
-
The present invention is directed to compounds of Formula (I): (Formula (I)) and pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R7, R8, R9, R11, n and p are defined herein. The compounds of Formula (I) are M1 receptor positive allosteric modulators that are useful in the treatment of diseases in which the M1 receptor is involved, including Alzheimer's disease, schizophrenia, pain and sleep disorders. The invention also relates to pharmaceutical compositions comprising a compound of Formula (I) and a pharmaceutically acceptable carrier, and to methods of using the compounds of Formula (I) in the treatment of diseases mediated by the M1 receptor.
- -
-
Page/Page column 39; 40
(2017/09/27)
-
- N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators
-
The present invention is directed to N-methyl tetrahydroquinoline compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
- -
-
-
- FUSED CYCLOPENTYL ANTAGONISTS OF CCR2
-
The present invention comprises compounds of Formula (I). wherein: R0, R1, R2, R3, R4, R5, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I)
- -
-
Page/Page column 45-46
(2013/10/22)
-
- DIHYDROBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
-
The present invention is directed to dihydrobenzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease
- -
-
Page/Page column 29-30
(2012/04/23)
-
- N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
-
The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
- -
-
Page/Page column 52
(2012/12/13)
-
- Heterocyclic amino acids for prostate cancer imaging
-
This invention relates to heterocyclic amino acid derivatives suitable for labeling or already labeled with 18F or 19F, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for imaging proliferative diseases.
- -
-
Page/Page column 32
(2011/12/14)
-
- PYRANYL ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
-
The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as ALzheimer?s disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor
- -
-
Page/Page column 42
(2011/04/14)
-
- NAPHTHALENE CARBOXAMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
-
The present invention is directed to naphthalene carboxamide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
- -
-
Page/Page column 44
(2011/12/14)
-
- HETEROCYCLIC AMINO ACIDS
-
This invention relates to heterocyclic amino acid derivatives suitable for labeling or already labeled with 18F or 19F, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for imaging proliferative diseases.
- -
-
Page/Page column 51-52
(2011/12/14)
-
- TETRAHYDROQUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
-
The present invention is directed to tetrahydroquinoline amide compounds of formula (I) (Formula should be inserted here) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
- -
-
Page/Page column 27
(2012/01/06)
-
- HETEROCYCLIC FUSED PHENANTHROLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
-
The present invention is directed to heterocyclic fused phenanthrolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
- -
-
Page/Page column 24-25
(2012/01/06)
-
- AMINOBENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
-
The present invention is directed to aminobenzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimers disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor
- -
-
Page/Page column 40-41
(2011/08/03)
-
- PYRIDOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
-
The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
- -
-
Page/Page column 38
(2011/07/07)
-
- QUINOLINE AMIDE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
-
The present invention is directed to quinoline amide compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
- -
-
Page/Page column 51-53
(2011/08/03)
-
- Morpholinosulfur trifluoride (morph-DAST)-mediated rearrangement in the fluorination of cyclic α,α-dialkoxy ketones toward 1,2-dialkoxy-1,2-difluorinated compounds
-
The deoxofluorination of cyclic α,α-dialkoxy ketones with morpholinosulfur trifluoride (Morph-DAST) resulted in 1,2-dialkoxy-1,2- difluorinated carbo- and heterocyclic compounds. The reaction proceeds via a 1,2-alkoxy migration leading to mixtures of cis-
- Surmont, Riccardo,Verniest, Guido,De Groot, Alex,Thuring, Jan Willem,De Kimpe, Norbert
-
scheme or table
p. 2751 - 2756
(2010/12/25)
-
- Highly stereoselective synthesis of new α-amino-β-hydroxy six-membered heterocyclic phosphonic acids, serine analogues
-
The synthesis of 2-hydroxy-4-heterocyclic phosphonic acids was achieved in a six-step sequence from the appropriate ketones. Thus, 2-hydroxyheterocyclic ketone acetals were prepared and then esterified by N-Boc-l-phenylalanine, used as a chiral auxiliary. The resulting heterocyclic acetal esters gave by a one-pot reaction bicyclic ketimines. These imines underwent nucleophilic addition with phosphite to provide efficiently and stereoselectively, under kinetic control, bicyclic aminophosphonates. Cleavage of the phenylalanine moiety by oxidation followed by acidic hydrolysis of the resulting heterocyclohexylphosphonates provided the new (4-amino-3-hydroxypiperidin-4-yl)-, (4-amino-3-hydroxytetrahydro-2H-pyran-4-yl)- and (1-amino-2-hydroxycyclohexyl)phosphonic acids.
- Louaisil, Nicolas,Rabasso, Nicolas,Fadel, Antoine
-
scheme or table
p. 8587 - 8595
(2009/12/09)
-
- Design, synthesis, and structure-activity relationship of novel CCR2 antagonists
-
A series of novel 1-aminocyclopentyl-3-carboxyamides incorporating substituted tetrahydropyran moieties have been synthesized and subsequently evaluated for their antagonistic activity against the human CCR2 receptor. Among them analog 59 was found to posses potent antagonistic activity.
- Kothandaraman, Shankaran,Donnely, Karla L.,Butora, Gabor,Jiao, Richard,Pasternak, Alexander,Morriello, Gregori J.,Goble, Stephen D.,Zhou, Changyou,Mills, Sander G.,MacCoss, Malcolm,Vicario, Pasquale P.,Ayala, Julia M.,DeMartino, Julie A.,Struthers, Mary,Cascieri, Margaret A.,Yang, Lihu
-
scheme or table
p. 1830 - 1834
(2009/11/30)
-
- α-Hydroxylation of carbonyls using iodine
-
The α-hydroxylation of ketones and aldehydes to α-hydroxyketals mediated by iodine under basic conditions in MeOH is described. Enolates generated under the reaction conditions are iodinated and the resulting α-iodocarbonyl is transformed into the hydroxyketal. The use of iodine for this chemistry represents an economical and practical alternative to existing methods for this transformation.
- Zacuto, Michael J.,Cai, Dongwei
-
p. 447 - 450
(2007/10/03)
-
- 3,3-DISUBSTITUTED TETRAHYDROPYRANYL CYCLOPENTYL AMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
-
Compounds of Formula I (wherein n, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, Y and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and im
- -
-
Page/Page column 25-26
(2008/06/13)
-
- TETRAHYDROPYRAN HETEROCYCLIC CYCLOPENTYL HETEROARYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
-
The present invention is further directed to compounds of the formulas: (I) (II) (wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R15, R16, R17, R18, R19, R24 and R25 are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.
- -
-
-
- TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROISOQUINOLINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
-
The present invention is directed to compounds of the formula I: I(wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.
- -
-
Page/Page column 70-71
(2010/02/07)
-
- TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
-
The present invention is directed to compounds of the formula (I): (wherein R3 et R8 are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.
- -
-
Page/Page column 18-19
(2010/02/07)
-
- Electro-organic Chemistry. Part 93. Electro-organic Transformation of Aldehydes and Ketones to α-Hydroxylated Acetals Utilizing Mediators and Some Synthetic Uses of the Products
-
Electro-oxidation of aldehydes (R1R2CHCHO) and ketones (R1R2CHCOR3) in methanol containing iodide ion (I-) and KOH gave the corresponding α-hydroxylated acetals in good yields.The first step of this oxidation is explained in terms of the attack of an anodically generated active iodine species 'I+' on enols of R1R2CHCHO and R1R2CHCOR3. α-Hydroxy acetals were useful starting materials as exemplified by reaction with aniline or methyl carbamates in the presence of Lewis acids to afford β-keto amine derivatives.The anodic oxidation of α-hydroxy acetals was also carried out.
- Shono, Tatsuya,Matsumura, Yoshihiro,Inoue, Kenji,Iwasaki, Fumiaki
-
-